General Biol Receives $100M Pre-IPO Investment

(VCBeat) May. 17, 2021 -- Recently, General Biological Systems (Anhui) Co., Ltd. ("General Biol"), a one-stop provider of biomedical (scientific research, diagnosis, new drug R&D) services and raw materials, located in Chuzhou, Anhui Province, announced the completion of a pre-IPO round of several hundred million yuan. 

This round of financing was led by LYFE Capital, with participation from Jinhe Capital, Addor Capital, Huayi Venture Capital, and Ancheng Capital. Haoyue Capital acted as the exclusive financial consultant for this funding. The funds raised will enable General Biol to further expand its R&D infrastructure and market in the life sciences services + raw materials and CRO/CDMO.

Founded in 2014, General Biol focuses on technology development and transformation in the field of life science and focuses on building a platform for synthetic biology research and application. General Biol applies its own technologies in many fields, including basic life science research, biomedical research and development, and core raw materials development of in vitro diagnostic products. The company has become the provider of comprehensive products and services in life science research and application.

General Biol now has five platforms of gene synthesis, industrial primer, analysis and testing, protein expression and antibody preparation, realizing the "one-stop" business integration from gene, protein and antibody, among which the technology and production scale of gene synthesis and industrial primer platform are in the leading level of the industry. General Biol focuses on building three major pipelines: life science research services/products, core raw materials and services of diagnostic reagents, and early research and development services of new drugs.

Founded in 2015, LYFE Capital is a dedicated healthcare fund with $1.27 billion in assets under management. Their investment focus spans biopharmaceuticals, medical devices, and diagnostics. LYFE Capital work closely with their portfolio companies to support their needs by providing capital and active support in global partnerships, collaborations, regulatory guidance and local market access.

Jinhe Capital focuses on the healthcare sector, headquartered in Guangzhou. The core team has more than 25 years of experience in the medical industry and has successfully helped to build KingMed, the largest third-party medical laboratory in China. At present, Jinhe Capital manages two medical industry funds with a scale of nearly 2 billion yuan. It continues to invest in the field of in vitro diagnosis and other fields to build an industrial ecosystem.